REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Trial Details
- NCT ID
- NCT07223307
- Phase
- PHASE2
- Sponsor
- Stanford University
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Locations (sample)
- Palo Alto, California, United States|37.44188,-122.14302
Key Eligibility Criteria
- Histologically confirmed HCC, intrahepatic cholangiocarcinoma, or metastatic cancer. In the case of suspected HCC in patients with known cirrhosis,…
- ≥ 18 years old at time of study enrollment
- Child-Pugh A status
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →